Effectiveness and Safety of Very Low Dose Combined Oral Contraceptive for the Treatment of Non-atypical Endometrial Hyperplasia: A Pilot Study

Authors

  • Pichai Leerasiri Department of Obstetrics and Gynecology, Faculty of Medicine Siriraj Hospital, Mahidol University
  • Manee Rattanachaiyanont Department of Obstetrics and Gynecology, Faculty of Medicine Siriraj Hospital, Mahidol University
  • Surasak Angsuwathana Department of Obstetrics and Gynecology, Faculty of Medicine Siriraj Hospital, Mahidol University
  • Kitirat Techatraisak Department of Obstetrics and Gynecology, Faculty of Medicine Siriraj Hospital, Mahidol University
  • Prasong Tanmahasamut Department of Obstetrics and Gynecology, Faculty of Medicine Siriraj Hospital, Mahidol University
  • Suchada Tanphatthana Department of Obstetrics and Gynecology, Faculty of Medicine Siriraj Hospital, Mahidol University

Keywords:

Endometrial Hyperplasia, Oral contraceptive, Progestin, Treatment

Abstract

Objective: A randomized control study to compare the effectiveness and the safety of very low dose oral contraceptive (OC) with progestin for the treatment of endometrial hyperplasia.
Methods: Ten patients with non-atypical endometrial hyperplasia who did not have contraindications for OC were randomized to receive either OC (Mercilon®) or progestin (Medroxy progesterone acetate: MPA) for 6 months at the Gynecologic Endocrinology Unit, Division of Reproductive Medicine, Department of Obstetrics and Gynecology, Faculty of Medicine Siriraj Hospital. Their main measured outcomes were endometrial histopathology and adverse events.
Results: Sixty percent (3 of 5) of the progestin group and 80% (4 of 5) of the OC group completed the 6-month therapy. All of them had normal endometrium by the end of the 6th cycle of treatment. Two cases in the progestin group and one case in the OC group withdrew from the study by the end of 1st cycle of treatment. No serious adverse event was detected during the study period.
Conclusion: OC may be as effective and safe as progestin for the treatment of non-atypical endometrial hyperplasia.

Downloads

Published

01-05-2006

How to Cite

Leerasiri, P. ., Rattanachaiyanont, M. ., Angsuwathana, S. ., Techatraisak, K., Tanmahasamut, P. ., & Tanphatthana, S. . (2006). Effectiveness and Safety of Very Low Dose Combined Oral Contraceptive for the Treatment of Non-atypical Endometrial Hyperplasia: A Pilot Study. Siriraj Medical Journal, 58(5), 795–798. Retrieved from https://he02.tci-thaijo.org/index.php/sirirajmedj/article/view/245823

Issue

Vol. 58 No. 5 (2006): May

Section

Original Article

License

Users are free to share, copy, and redistribute all articles published in the Siriraj Medical Journal (SMJ) in any medium or format as long as you follow the following terms:

  • Attribution — You must give appropriate credit, provide a link to the material, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the publisher endorses you or your use.
  • NonCommercial — You may not use the material for commercial purposes.
  • NoDerivatives — If you remix, transform, or build upon the material, you may not distribute the modified material.
  • No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.